Can a patient commence treatment whilst awaiting CGP results?
For patients with symptomatic or bulky disease, where it would be detrimental to delay treatment, up to 2 cycles of
standard of care systemic therapy are allowed prior to commencing an ASPiRATION therapeutic substudy. Note that clinical trials than ASPiRATION substudies may not allow commencement of treatment prior to enrolment.
Impact
The ASPiRATION program is the first of its kind in Australia to generate high-quality, real-world data about the impact and value of comprehensive genomic profiling (CGP) in delivering precision medicine and personalised healthcare. Identifying actionable molecular targets through CGP provides patients with opportunities to receive novel targeted treatments via therapeutic substudies.
Progress
Molecular screening for ASPiRATION commenced in late 2020, with eleven of the fifteen planned participating hospitals throughout Australia open for screening.
Substudies are also open for enrolment at selected sites.
For progress on ethics. governance and study start up at particular sites, contact the NHMRC Clinical Trial Centre via most@ctc.usyd.edu.au